Proficiency of clinical laboratories in Spain in detecting vancomycin-resistant Enterococcus spp. The Spanish VRE Study Group.
Studies in a variety of U.S. clinical laboratories have demonstrated difficulty in detecting intermediate and low-level vancomycin-resistant enterococci (VRE). The misclassification of "at least intermediate resistant isolates" as vancomycin susceptible may have both clinical implications and a negative impact on measures to control the spread of VRE. No published study has assessed the ability of clinical laboratories in Europe to detect VRE. So, the apparent low prevalence of VRE in European hospitals may be, in part, secondary to the inability of these laboratories to detect all VRE. In an effort to assess European laboratories' proficiency in detecting VRE, we identified 22 laboratories in Spain and asked them to test four VRE strains and one susceptible enterococcal strain from the Centers for Disease Control and Prevention collection. Each organism was tested by the routine antimicrobial susceptibility testing method used by each laboratory. Overall, VRE were correctly identified in 61 of 88 (69.1%) instances. The accuracy of VRE detection varied with the level of resistance and the antimicrobial susceptibility method. The high-level-resistant strain (Enterococcus faecium; MIC, 512 microg/ml) was accurately detected in 20 of 22 (91. 3%) instances, whereas the intermediate-resistant isolate (Enterococcus gallinarum; MIC, 8 microg/ml) was accurately detected in only 11 of 22 (50%) instances. Classification errors occurred in 27 of 88 (30.9%) instances. Misclassification as vancomycin susceptible was the most common error (16 of 27 [59.3%] instances). Our study shows that the participating Spanish laboratories had an overall acceptable proficiency in detecting VRE but that a substantial proportion of VRE isolates with low or intermediate levels of resistance were not detected. We recommend that studies be conducted to validate laboratory proficiency testing as an important step in the prevention and control of the spread of antimicrobial resistance.
Alonso-Echanove
J
J
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Robles
B
B
Jarvis
W R
WR
D002487:Centers for Disease Control and Prevention, U.S.; D019411:Clinical Laboratory Techniques / Q000592:standards*; D016983:Enterococcus / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification*; D013293:Enterococcus faecalis / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D016984:Enterococcus faecium / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D005060:Europe; D006801:Humans; D007753:Laboratories / Q000592:standards*; D008826:Microbial Sensitivity Tests; D011785:Quality Assurance, Health Care; D013030:Spain; D014481:United States; D014640:Vancomycin / Q000494:pharmacology*; D018440:beta-Lactam Resistance
D014640:Vancomycin